No quarterly revenue total was found in LANTERN PHARMA INC.'s SEC filings.
Lantern Pharma Inc. (LTRN) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $7.4 million in cash and investments and $39,715 in total debt.
Revenue
—
Net income
$-7.07M
-63.3% vs year-ago quarter
Operating cash flow
$-2.94M
+25.3% vs year-ago quarter
Free cash flow
$-2.79M
+29.8% vs year-ago quarter
EPS
$-0.57
-42.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
12.78M
+18.4% vs year-ago quarter
Net cash
$7.32M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LTRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1763950
- Former names
- Lantern Pharma (until Jan 14, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.5M | -$3.4M | -$4.2M | -$4.3M | -$4.7M |
| Net income | -$7.1M | -$3.3M | -$4.1M | -$4.2M | -$4.3M |
| Diluted EPS | -$0.57 | -$0.30 | -$0.36 | -$0.39 | -$0.40 |
| Operating cash flow | -$2.9M | -$3.8M | -$2.8M | -$4.6M | -$3.9M |
| Free cash flow | — | — | -$2.8M | -$4.6M | -$3.9M |
| Total assets | $8.6M | $7.2M | $11.0M | $13.6M | $17.4M |
| Total liabilities | $11.8M | $3.8M | $4.5M | $4.0M | $4.9M |
| Stockholders' equity | -$3.2M | $3.4M | $6.5M | $9.6M | $12.5M |
| Cash and investments | $7.4M | $6.3M | $10.1M | $12.4M | $15.9M |
| Total debt | $39,715 | $59,076 | $78,539 | $93,954 | $145,039 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 21, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Listing notice
|
Oct 1, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 30, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2026 | Aug 14, 2026 |
All 262 Lantern Pharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.